Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

@article{Borger2014CirculatingO2,
  title={Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.},
  author={Darrell R. Borger and Lipika Goyal and Thomas Ho Lai Yau and Ronnie Tung-ping Poon and Marek A Ancukiewicz and Vikram Deshpande and David C. Christiani and Hannah M. Liebman and Huan Yang and Hyeryun Kim and Katharine E. Yen and Jason Edward Faris and Anthony John Iafrate and Eunice Lee Kwak and Jeffrey T. Clark and Jill N. Allen and Lawrence Scott Blaszkowsky and Janet E. Murphy and Supriya Kumar Saha and Theodore S. Hong and Jennifer Yon-Li Wo and Cristina R Ferrone and Kenneth K Tanabe and Nabeel Bardeesy and Kimberly S. Straley and Sam Agresta and David P. Schenkein and Leif William Ellisen and David P. Ryan and Andrew X. Zhu},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 7},
  pages={1884-90}
}
PURPOSE Mutations in the IDH1 and IDH2 (IDH1/2) genes occur in approximately 20% of intrahepatic cholangiocarcinoma and lead to accumulation of 2-hydroxyglutarate (2HG) in the tumor tissue. However, it remains unknown whether IDH1/2 mutations can lead to high levels of 2HG circulating in the blood and whether serum 2HG can be used as a biomarker for IDH1/2 mutational status and tumor burden in intrahepatic cholangiocarcinoma. EXPERIMENTAL DESIGN We initially measured serum 2HG concentration… CONTINUE READING
26 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…